Plain-English translation of NCT05413655 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing a new medication called for people with early Alzheimer's disease. You would take the medication as a pill every day in addition to any Alzheimer's medications you're already taking. The study will randomly assign you to take one of two doses of the medication or a placebo (a pill with no active ingredient) to see if this treatment helps slow memory and thinking problems.
Current Alzheimer's treatments help some people, but doctors are looking for new ways to slow memory loss and cognitive decline in the early stages of the disease. This medication is being tested to see if it can offer additional benefit when added to treatments people are already using.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic multiple times over the course of the study to take cognitive tests, have blood work done, and receive your assigned medication (either at one of two doses or placebo). You would take a daily pill at home and keep track of how you're feeling. The study involves 120 participants total, and you would have an equal chance of receiving the active medication or placebo.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Taiwan
Phase
Testing effectiveness
Sponsor
Excelsior
Collaborators
Formosa Biomedical Technology Corp.
Enrollment target
~120 participants
Started
August 2022
Primary completion
December 2026
Age range
50 Years – 80 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cliff Lin
Kaohsiung Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.